Table 5.

Completed and ongoing clinical trials targeting galectins in oncology

NCT Number	Intervention	Target	Condition	Phase	Status
NCT05240131	GB1211 combined with Atezolizumab	Gal-3	Non-small cell lung cancer	I/II	Recruiting
NCT01724320	OTX008	Gal-1	Solid tumors	I	Unknown
NCT02575404	GR-MD-02 combined with Pembrolizumab (anti-PD-L1)	Gal-3	Melanoma, non-small cell lung cancer, and squamous cell head and neck cancers	I	Active, not recruiting
NCT00388700	GM-CT-01 combined with 5-FU, Avastin and Leucovorin	Gal-1&3	Colorectal cancer	II	Withdrawn
NCT00110721	GM-CT-01 plus 5-FU	Gal-1&3	Colorectal cancer	II	Terminated
NCT00386516	GM-CT-01 combined with 5-FU	Gal-1&3	Bile duct cancer Gallbladder cancer	II	Withdrawn
NCT00054977	GM-CT-01 with and without 5-FU	Gal-1&3	Colorectal, lung, breast, head and neck, and prostate cancers	I	Completed
NCT04666688	LYT-200 alone or combined with Gemcitabine/nab-paclitaxel or Anti-PD-1	Gal-9	Metastatic cancer, solid tumor, cholangiocarcinoma	I/II	Recruiting
NCT04987996	GR-MD-02 plus Pembrolizumab or Pembrolizumab	Gal-3	Melanoma, head and neck squamous cell carcinoma	II	Suspended
NCT01681823	Dietary Supplement: PectaSol-C Modified Citrus Pectin (MCP)	Gal-3	Prostatic neoplasms	II	Completed
NCT01723813	Peptide vaccinations plus GM-CT-01	Gal-3	Metastatic melanoma	I/II	Terminated
NCT02117362	GR-MD-02 and Ipilimumab	Gal-3	Metastatic melanoma	I	Completed
NCT00776802	GCS-100 combined with Etoposide and Dexamethasone	Gal-3	Diffuse large B-cell lymphoma	I/II	Withdrawn

Data were collected from the NIH Clinical Trials website (https://clinicaltrials.gov/, till Dec 2022)